EFFICACY AND SAFETY OF COTADUTIDE, A DUAL GLP1-GLUCAGON RECEPTOR AGONIST, IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND T2DM

被引：0
|
作者：
Selvarajah, Viknesh [1 ]
Robertson, Darren [1 ]
Hansen, Lars [2 ]
Jermutus, Lutz [1 ]
Smith, Kirsten [1 ]
Frickleton, Celeste [2 ]
Coggi, Angela [1 ]
Sanchez, Jose [3 ]
Chang, Yi-Ting [2 ]
Parker, Victoria [1 ]
机构：
[1] AstraZeneca, Res & Early Dev, Cardiovasc Renal & Metab, BioPharmaceut R&D, Cambridge, England
[2] AstraZeneca, Res & Early Dev, Cardiovasc Renal & Metab, BioPharmaceut R&D, Gaithersburg, MD USA
[3] AstraZeneca, Res & Early Dev, Cardiovasc Renal & Metab, BioPharmaceut R&D, Molndal, Sweden
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
3000
引用
收藏
页码：I87 / I87
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease
    Ding, Kaiyue
    Li, Zhuoyu
    Lu, Yingying
    Sun, Lin
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2023, 115 : 114 - 127
  • [42] 22. Long-Term Safety and Efficacy of Dapagliflozin in Patients with T2DM and Cardiovascular Disease (106-OR)
    William T. Cefalu
    Lawrence A. Leiter
    Eva Johnsson
    Jennifer Sugg
    Ingrid Gause-Nilsson
    Nederlands Tijdschrift voor Diabetologie, 2015, 13 (3) : 77 - 78
  • [43] FDA APPROVAL AND PRICE ANALYSIS FOR GLUCAGON-LIKE PEPTIDE-RECEPTOR AGONIST (GLP-1 RA) FOR T2DM AND OBESITY: A DESCRIPTIVE STUDY (DURING THE PERIOD OF 2005-2016)
    Alzarea, A., I
    Simonetti, J.
    Zaghloul, I
    Tyrrell, B.
    Mekary, R. A.
    VALUE IN HEALTH, 2017, 20 (05) : A168 - A168
  • [44] Evaluation of the Progression of Chronic Kidney Disease (CKD) and Associated Costs in US Patients with Type 2 Diabetes Mellitus (T2DM)
    Neslusan, Cheryl
    Montejano, Leslie
    O'Brien, Duncan
    Cuddihy, Robert
    DIABETES, 2016, 65 : A327 - A328
  • [45] Efficacy and Safety of Ertugliflozin in Hispanic/Latino Patients (Pts) with Type 2 Diabetes Mellitus (T2DM)
    Liu, Jie
    Tarasenko, Lisa
    Ellison, Misoo C.
    Pong, Annpey
    Huyck, Susan
    Mancuso, James P.
    Terra, Steven G.
    Gantz, Ira
    DIABETES, 2019, 68
  • [46] Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3)
    Ludvik, Bernhard
    Giorgino, Francesco
    Jodar, Esteban
    Frias, Juan Pablo
    Lando, Laura Fernandez
    Brown, Katelyn
    Bray, Ross
    Rodriguez, Angel
    DIABETES, 2021, 70
  • [47] The Long-Term Efficacy and Safety of Canagliflozin in Combination with Insulin in Japanese Patients with T2DM
    Harashima, Shinichi
    Inagaki, Nobuya
    Kaku, Kohei
    Kondo, Kazuoki
    Maruyama, Nobuko
    Otsuka, Makiko
    Kawaguchi, Yutaka
    Watanabe, Yumi
    Goda, Maki
    Iijima, Hiroaki
    DIABETES, 2017, 66 : A34 - A34
  • [48] Safety and efficacy comparison of different insulin regimens in T2DM patients: A meta-analysis
    Gao, Xueying
    Cai, Xiaoling
    Yang, Wenjia
    Ji, Linong
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S197 - S197
  • [49] Safety and Efficacy of Long-Term Pioglitazone Treatment for Patients With Prediabetes or T2DM and NASH
    Cusi, Kenneth
    Orsak, Beverly
    Lomonaco, Romina
    Finch, Joan
    Ortiz-Lopez, Carolina
    Bril, Fernando
    Diaz, Norma
    Kaminski-Graham, Rose
    Darland, Celia
    Musi, Nicolas
    Webb, Amy
    Hardies, Jean
    Tio, Fermin
    DIABETES, 2013, 62 : A309 - A309
  • [50] Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus (T2DM) and Concomitant Heart Failure
    Kosiborod, Mikhail
    Gause-Nilsson, Ingrid Ami
    Sonesson, Christian
    Sugg, Jennifer E.
    Johnsson, Eva
    DIABETES, 2015, 64 : A313 - A313
12345